Recursion Pharmaceuticals, Inc. $RXRX Shares Sold by Liontrust Investment Partners LLP

Key Points

• Liontrust Investment Partners LLP reduced its stake in Recursion Pharmaceuticals by 36.1%, now holding 595,055 shares valued at approximately $3.15 million.
• Recursion Pharmaceuticals reported a loss of $0.41 EPS for the last quarter, which was below analysts' expectations, although revenue increased by 33.3% year-over-year.
• Wall Street analysts maintain an average rating of "Hold" on Recursion Pharmaceuticals with a consensus target price of $7.00, following mixed reviews from several research firms.

Liontrust Investment Partners LLP decreased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 36.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 595,055 shares of the company's stock after selling 336,672 shares during the quarter. Liontrust Investment Partners LLP owned approximately 0.15% of Recursion Pharmaceuticals worth $3,148,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Ensign Peak Advisors Inc raised its stake in Recursion Pharmaceuticals by 0.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after acquiring an additional 1,300 shares during the period. Summit Investment Advisors Inc. raised its stake in Recursion Pharmaceuticals by 7.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after acquiring an additional 1,875 shares during the period. Clear Creek Financial Management LLC grew its position in Recursion Pharmaceuticals by 9.8% in the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after purchasing an additional 1,907 shares during the last quarter. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares during the last quarter. Finally, QRG Capital Management Inc. grew its position in Recursion Pharmaceuticals by 8.5% in the 1st quarter. QRG Capital Management Inc. now owns 28,515 shares of the company's stock worth $151,000 after purchasing an additional 2,244 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Insider Activity

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares in the company, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 8.43% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have commented on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals has an average rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded down $0.3050 on Wednesday, hitting $4.7850. The company had a trading volume of 20,592,542 shares, compared to its average volume of 24,865,205. The business has a 50-day simple moving average of $5.48 and a 200-day simple moving average of $5.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The company has a market cap of $2.08 billion, a PE ratio of -2.69 and a beta of 0.93. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The company had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company's revenue was up 33.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.40) earnings per share. Research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.